Monalizumab
As of the edition of 20 October 2026, Monalizumab is an antibody: in active development; acts on KLRC1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody
- Registered trials
- 23, 4 stopped early
- Disease areas
- Cancer; Lungs and airways; Blood and lymph; Digestive system; Ear, nose and throat; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Monalizumab.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | P26715 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 2 | 0 | 0 |
| Phase 2 | 18 | 5 | 7 | 4 |
| Phase 3 | 2 | 0 | 2 | 0 |
| All trials | 23 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Innate Pharma | Lead sponsor of trials | 2014 to now |
| AstraZeneca | Lead sponsor of trials | 2016 to now |